Evidence map›Paper›PMID 21626222›Full record

Trial reportPediatric nephrology (Berlin, Germany)2011

Cyclosporine A vs. methylprednisolone for Henoch-Schönlein nephritis: a randomized trial.

Outi Jauhola, Jaana Ronkainen, Helena Autio-Harmainen, Olli Koskimies, Marja Ala-Houhala, Pekka Arikoski, Tuula Hölttä, Timo Jahnukainen, Jukka Rajantie, Timo Ormälä and 1 more

Erratum issued Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Pediatric nephrology (Berlin, Germany), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT00425724 (HSP-glomerulonephritis Trial), which is not on this map. Cited by 38 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 5 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00425724 phase4completednot on this map

HSP-glomerulonephritis Trial: MP vs CyA

TypeinterventionalSponsorOulu University HospitalRan2000 to 2011Enrolled20ConditionsPurpura, Schoenlein-HenochArmsMethylprednisolone pulses plus prednisone versus Cyclosporine A
3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 5 syntheses or guidelines pooled it, 91 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Guideline
  4. Pooled it
  5. Pooled it
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Observational
  12. Review
  13. Interventions for preventing and treating kidney disease in IgA vasculitis.The Cochrane database of systematic reviews · 2023
    Review
  14. Article
  15. Article
  16. [Update on immunoglobulin A vasculitis].Zeitschrift fur Rheumatologie · 2022
    Review
  17. Review
  18. Review
  19. Review
  20. IntravenousCase reports in pediatrics · 2020
    Article
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

11 authors at 7 institutions in 1 country.

Outi JauholaDepartment of Children and Adolescents, Oulu University Hospital, PO Box 23, 90029, Oulu, Finland. ojauhola@paju.oulu.fi
Jaana Ronkainen
Helena Autio-Harmainen
Olli Koskimies
Marja Ala-Houhala
Pekka Arikoski
Tuula Hölttä
Timo Jahnukainen
Jukka Rajantie
Timo Ormälä
Matti Nuutinen
Oulu University Hospital · FIHelsinki Children's Hospital · FIHyvinkää Hospital · FIJorvi Hospital · FIKuopio University Hospital · FITampere University Hospital · FIUniversity of Helsinki · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Knowledge about how to treat severe Henoch-Schönlein nephritis (HSN) is scarce. The aim of our study is to compare cyclosporine A (CyA) and methylprednisolone pulses (MP) in the treatment of severe HSN. Out of 24 pediatric HSN patients with nephrotic-range proteinuria or crescentic HSN in kidney biopsy, seven were randomized to receive CyA for 12 months at an initial dose of 5 mg/kg and eight to receive 3 MP pulses of 30 mg/kg followed by prednisone for 4 months. The other nine patients received identical treatment without randomization. Kidney biopsies were performed at inclusion and after 2 years. The primary outcomes were the duration of proteinuria and hematuria, estimated glomerular filtration rate, and renal biopsy histology. All the 11 CyA-treated patients achieved resolution of nephrotic-range proteinuria within 3 months, while the MP-group response was slower, and in 6/13 was not achieved with the initial treatment. Additional immunosuppressive treatment was needed in none of the CyA-treated patients but in six patients treated with MP (difference in proportion 46%, p = 0.008). The 2-year control biopsies were similarly improved in both groups. After mean 6.1 years (2.2-10.4 years), 16 patients (eight CyA, eight MP) had no renal symptoms and six (three CyA, three MP) had persistent nephropathy but normal renal function. One MP-treated patient had reduced renal function and another had developed ESRD and received a renal transplant. CyA gave a 100% resolution of nephrotic-range proteinuria and a 100% renal survival rate without additional therapy after a mean follow-up of 6 years. Treatment of HSN with CyA is efficacious, safe and not inferior to MP.

Indexed as

AdolescentChildChild, PreschoolCyclosporineFemaleHumansIgA VasculitisImmunosuppressive AgentsMaleMethylprednisoloneNephritisCyclosporineImmunosuppressive AgentsMethylprednisolone

Identifiers

PMID21626222
OpenAlexW1971491273

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.